Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development

被引:24
作者
Polasek, Thomas M. [1 ,2 ]
Rayner, Craig R. [1 ,2 ]
Peck, Richard W. [3 ]
Rowland, Andrew [4 ]
Kimko, Holly [5 ]
Rostami-Hodjegan, Amin [1 ,6 ]
机构
[1] Certara, 100 Overlook Ctr,Suite 101, Princeton, NJ 08540 USA
[2] Monash Univ, Ctr Med Use & Safety, Melbourne, Vic, Australia
[3] Roche Innovat Ctr Basel, Pharm Res & Exploratory Dev, Basel, Switzerland
[4] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[5] Janssen Res & Dev, Exton, PA USA
[6] Univ Manchester, Ctr Appl Pharmacokinet, Manchester, Lancs, England
来源
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2019年 / 8卷 / 04期
关键词
drug development; model-informed precision dosing; physiologically based pharmacokinetics; precision dosing; precision medicine; PHYSIOLOGICALLY-BASED PHARMACOKINETICS; PBPK; SIMULATION; POPULATION; PREDICTION; MEDICINE; ONCOLOGY; PATIENT; IMPACT; ADME;
D O I
10.1002/cpdd.638
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Model-informed precision dosing (MIPD) is biosimulation in healthcare to predict the drug dose for a given patient based on their individual characteristics that is most likely to improve efficacy and/or lower toxicity compared with traditional dosing. Despite widespread use of biosimulation in drug development, MIPD has not been adopted beyond academic-hospital centers. A reason for this is that MIPD requires more supporting evidence in the language that everyday doctors understand-evidence-based medicine. In this commentary, codevelopment of companion MIPD tools during drug development is advocated as a way to accelerate the generation of the evidence required for broader clinical implementation of MIPD. Such tools have the potential to evolve into "dynamic" prescribing information that could guide dose selection for complex patients.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 55 条
  • [1] Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician
    Abdel-Rahman, Susan M.
    Breitkreutz, Matthew L.
    Bi, Charlie
    Matzuka, Brett J.
    Dalal, Jignesh
    Casey, K. Leigh
    Garg, Uttam
    Winkle, Sara
    Leeder, J. Steven
    Breedlove, JeanAnn
    Rivera, Brian
    [J]. FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [2] Impact of Modeling and Simulation: Myth or Fact?
    Allerheiligen, S. R. B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) : 413 - 415
  • [3] Barriers to the acceptance of electronic medical records by physicians from systematic review to taxonomy and interventions
    Boonstra, Albert
    Broekhuis, Manda
    [J]. BMC HEALTH SERVICES RESEARCH, 2010, 10
  • [4] Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
    Brussee, Janneke M.
    Yu, Huixin
    Krekels, Elke H. J.
    Palic, Semra
    Brill, Margreke J. E.
    Barrett, Jeffrey S.
    Rostami-Hodjegan, Amin
    de Wildt, Saskia N.
    Knibbe, Catherijne A. J.
    [J]. PHARMACEUTICAL RESEARCH, 2018, 35 (09)
  • [5] Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach
    Bullock, Julie M.
    Lin, Tiffany
    Bilic, Sanela
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (10) : S105 - S115
  • [6] A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer
    Cheeti, Sravanthi
    Budha, Nageshwar R.
    Rajan, Sharmila
    Dresser, Mark J.
    Jin, Jin Y.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (03) : 141 - 154
  • [7] Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
    Darwich, A. S.
    Ogungbenro, K.
    Vinks, A. A.
    Powell, J. R.
    Reny, J-L
    Marsousi, N.
    Daali, Y.
    Fairman, D.
    Cook, J.
    Lesko, L. J.
    McCune, J. S.
    Knibbe, C. A. J.
    de Wildt, S. N.
    Leeder, J. S.
    Neely, M.
    Zuppa, A. F.
    Vicini, P.
    Aarons, L.
    Johnson, T. N.
    Boiani, J.
    Rostami-Hodjegan, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (05) : 646 - 656
  • [8] Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs
    Darwich, Adam S.
    Ogungbenro, Kayode
    Hatley, Oliver J.
    Rostami-Hodjegan, Amin
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S1512 - +
  • [9] Dinh JC, 2018, CLIN PHARMACOL THER, V103, pS29
  • [10] Product information for generic drugs: old, unloved and sometimes unsafe
    Doogue, M. P.
    Thynne, T. R. J.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (12) : 1346 - 1348